Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis

News

December 1, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on November 22, 2022, entitled, “Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis.” continue reading »

Oncotarget | Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more

News

November 29, 2022
A new review was published in Oncotarget's Volume 13 on November 17, 2022, entitled, “Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more.” continue reading »

Oncotarget | Treasures from trash in cancer research

News

November 23, 2022
PRESS RELEASE: On November 17, 2022, a new research perspective was published in Oncotarget, entitled, “Treasures from trash in cancer research.” continue reading »

Oncotarget | Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

News

November 21, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on November 17, 2022, entitled, “Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention.” continue reading »

Oncotarget | Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas

News

November 17, 2022
PRESS RELEASE: On November 17, 2022, Oncotarget published a new research paper, entitled, “Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas.” continue reading »